Novelion Therapeutics (NVLN) Posts Q2 Loss of $0.08 on Revenue of $40.9M

Novelion Therapeutics (NASDAQ: NVLN) reported Q2 EPS of ($0.08). Revenue was $40.9 million compared to the prior year’s second quarter net revenues of $0

2017 Financial Guidance

The Company is revising its previously stated net revenues financial guidance for full year 2017 and now expects:

• Total net revenues between $135 million and $145 million, compared to the prior range of between $155 million and $165 million;
• MYALEPT net revenues between $65 million and $70 million, compared to the prior range of between $75 million and $80 million; and
• JUXTAPID net revenues between $70 million and $75 million, compared to the prior range of between $80 million and $85 million.

For earnings history and earnings-related data on Novelion Therapeutics (NVLN) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c